BrightSpring Health Services (BTSG) told analysts at the Wells Fargo 21st Annual Healthcare Conference on September 10 that growth is broadening across its operating segments, with pharmacy earnings before interest, taxes, depreciation and amortization (EBITDA) accelerating sharply after years of steady gains.
CFO Jennifer Phipps said pharmacy EBITDA growth, which ranged between 6% and 8% from 2022 through 2024, climbed to nearly 40% in 2025 and remained above 40% in the first half of 2026. The provider business, which includes Amedisys and LHC, posted organic EBITDA growth of about 20% in the most recent quarter.
The company also provided updated guidance on the impact of the Inflation Reduction Act drug-price negotiations. Phipps identified 2026 as the peak year for the policy’s effect on BrightSpring’s costs, estimating a mitigated net EBITDA impact of approximately $15 million. She projected the 2027 impact to be roughly half of the 2026 figure before further mitigation.
Phipps noted that the firm’s leverage ratio is approaching 2 times net debt to EBITDA, down from just over 4 times at the time of its initial public offering two and a half years ago. Management reaffirmed a long-term target in the mid-2x range.
On acquisitions, BrightSpring has completed more than 85 deals since inception, with all but two delivering EBITDA ahead of original targets and a pro forma acquisition multiple below 4x. The company outlined future deal sizes ranging from small tuck-ins under $5 million in EBITDA to larger transactions in the $10 million to $15 million range, with occasional opportunities in the $15 million to $50 million band.
Phipps also addressed operational dynamics around long-acting depot (LDD) medications, stating that programs typically take two to four years to reach full maturity. Visibility on new LDD wins usually appears 12 to 18 months ahead, and drugs launched as far back as 2021 continued to contribute to growth.
Regarding generic conversions, she pointed to the 2026 cohort, led by Pomalyst, which saw near‑100% patient conversion shortly after its launch in early Q1. The cohort also includes Bosulif and Rydapt. A second wave of generics is expected later this year, with most financial impact flowing into 2028.
BrightSpring disclosed that its artificial‑intelligence team now numbers about 30 people. The company began evaluating AI technologies roughly 24 months ago and started a serious buildout about a year ago. As an example, Phipps cited an acute infusion referral that involves a 300‑page medical file; manual processing previously took 45 minutes per case, while new AI tools aim to execute the task much faster.
On capital return, management indicated it aims to keep the share count flat at a minimum over the next couple of years. Share repurchases could resume in nine to 12 months, depending on cash flow generation and ongoing deal activity.
Shares of BrightSpring closed at $60.36, down 2.63% from the previous close of $61.99, trading within a 52‑week range of $25.93 to $73.75.
